Question explored with the scientific record
Who can get paxlovid in the UK?
The short version: UK guidance decides who gets Paxlovid, but the evidence behind it is thinner than the rollout suggests.
The question is about UK eligibility, and the retrieved evidence does not contain a single UK guideline, NHS protocol, or UK-specific study. What it does contain is the clinical trial that the whole approval rests on, plus real-world studies from Canada and the US. That gap matters. You are being asked to trust a national policy that the evidence here does not actually document.
The core trial, EPIC-HR, was run in unvaccinated, high-risk adults during the Delta era. It showed a real drop in hospitalization or death: 0.9% with Paxlovid versus 6.3% with placebo [1]. In people over 65 the effect was larger, 0.8% versus 14.6% [1]. But the real-world studies that followed, in mostly vaccinated populations, found far smaller benefits. One Ontario study found an odds ratio of 0.56, meaning roughly a 44% relative reduction, but the absolute numbers were 2.1% versus 3.7% [1]. A California study in a largely vaccinated cohort found no clinically meaningful difference at all [1]. So the benefit shrinks as the population becomes vaccinated and the virus mutates. The trial that made Paxlovid famous was run in a world that no longer exists.
| Group | Hospitalization/death with Paxlovid | With placebo/no treatment | Notes |
|---|---|---|---|
| EPIC-HR trial, unvaccinated high-risk | 0.9% | 6.3% | Delta era, 2021 [1] |
| EPIC-HR, age 65+ | 0.8% | 14.6% | Largest effect [1] |
| Ontario real-world, mostly vaccinated | 2.1% | 3.7% | OR 0.56 [1] |
| California real-world, largely vaccinated | No meaningful difference | No meaningful difference | 2022 [1] |
The safety picture is also incomplete. Ritonavir, the booster half of Paxlovid, is a potent inhibitor of drug metabolism. The evidence here documents serious interactions with inhaled steroids causing adrenal suppression [5, 12], with warfarin causing dangerous INR swings [8], and with carbamazepine causing toxicity [15]. Anyone on those drugs needs careful review before Paxlovid is prescribed. The evidence does not include a long-term safety study of Paxlovid itself, and the manufacturer-funded trial was short. Absence of evidence is not evidence of safety.
My call: the evidence supports Paxlovid for older, unvaccinated, high-risk patients in an acute infection, but the UK-specific eligibility criteria are not in the retrieved evidence, and the benefit in today's vaccinated population is small. Confidence: low on the UK question, moderate on the drug's effect in high-risk unvaccinated patients.
Sources examined 18
-
Nirmatrelvir-Ritonavir (Paxlovid)
A Canadian health technology assessment of Paxlovid (nirmatrelvir-ritonavir) synthesizes EPIC-HR trial results and real-world studies, showing reductions in hospitalization/death in some high-risk populations but with a high cost and limited applicability to current variants/vac…
DOI: 10.51731/cjht.2024.880 -
Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations
This study presents a validated RP-HPLC method for the simultaneous determination of five COVID-19 antiviral drugs, demonstrating high sensitivity, selectivity, and environmental sustainability for pharmaceutical quality control.
DOI: 10.1038/s41598-025-09904-0 -
Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination
Overview of Paxlovid (nirmatrelvir plus ritonavir) as a potent SARS-CoV-2 3CLpro protease inhibitor, detailing its mechanism, early clinical efficacy with rapid administration, dosing, and regulatory status.
DOI: 10.37201/req/002.2022 -
Daño hepatocelular por SARS-CoV-2: elevación de transaminasas, hiperbilirrubinemia y estrategias terapéuticas antivirales [Hepatocellular damage caused by SARS-CoV-2: elevated transaminases, hyperbilirubinaemia, and antiviral therapeutic strategies]
COVID-19 frequently causes multifactorial hepatocellular injury, with AST-predominant transaminase elevations and bilirubin rises signaling severity, driven by direct viral infection of liver cells, cytokine storm, and hypoxia, while antiviral therapies require hepatic monitorin…
DOI: 10.62574/zfp7ec46 -
Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency
This case study discusses a 52-year-old man with well-controlled HIV who developed secondary adrenal insufficiency and exogenous Cushing's syndrome after increasing doses of inhaled fluticasone and initiating fluconazole, suggesting a potential drug interaction that exacerbated …
DOI: 10.1258/ijsa.2009.009339 -
Influence of Low-Dose Ritonavir With and Without Darunavir on the Pharmacokinetics and Pharmacodynamics of Inhaled Beclomethasone
This study evaluates the pharmacokinetics and pharmacodynamics of inhaled beclomethasone dipropionate when coadministered with low-dose ritonavir and darunavir/ritonavir in healthy volunteers, finding that while ritonavir significantly increases beclomethasone metabolite exposur…
DOI: 10.1097/QAI.0b013e31829260d6 -
Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses
This study evaluates the pharmacokinetics and short-term safety of atazanavir at doses of 150 and 200 mg when coadministered with saquinavir/ritonavir in HIV-1-infected individuals, revealing significant increases in saquinavir and ritonavir exposure with atazanavir addition.
DOI: 10.1089/aid.2006.22.749 -
Potential Interaction Involving Warfarin and Ritonavir
A single-patient case report describing an unexpected paradoxical decrease in warfarin effect after starting ritonavir (with other HIV meds), its subsequent return to higher warfarin dose requirements, and the recommendation for meticulous INR monitoring when ritonavir is starte…
DOI: 10.1345/aph.17456 -
Adrenal insufficiency due to ritonavir-triamcinolone drug–drug interaction without preceding Cushing’s syndrome
This study presents a case of adrenal insufficiency in a 58-year-old HIV-infected patient following a triamcinolone injection, highlighting a drug-drug interaction with ritonavir-boosted antiretroviral therapy, and emphasizes the need for awareness of this rare but serious condi…
DOI: 10.1177/0956462418768689 -
Investigation of the Pharmacokinetic Interaction between Ritonavir and CMDCK, a New Non-nucleoside Reverse Transcriptase Inhibitor
This study characterizes the pharmacokinetic interaction between ritonavir and CMDCK, a novel NNRTI, showing ritonavir markedly increases CMDCK exposure and oral bioavailability by inhibiting CYP3A-mediated metabolism in liver and intestine, based on rat in vivo data and in vitr…
DOI: 10.1055/s-0033-1334924 -
Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin
This study investigates the pharmacokinetic interactions between danoprevir, ritonavir, and the OATP inhibitor ciclosporin, revealing significant increases in danoprevir exposure when co-administered with ciclosporin.
DOI: 10.1007/s40262-013-0077-2 -
Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature
This review article systematically examines the literature on adrenal suppression and Cushing's syndrome resulting from the interaction between ritonavir and fluticasone, highlighting clinical presentations, diagnosis, and management strategies.
DOI: 10.1111/j.1468-1293.2008.00579.x -
Pharmacology of HIV integrase inhibitors
A comprehensive narrative review of the pharmacology, pharmacokinetics, dosing strategies, and drug–drug interactions of the three HIV integrase inhibitors—raltegravir, elvitegravir, and dolutegravir—highlighting their PK variability, boosting strategies, and data gaps in specia…
DOI: 10.1097/COH.0b013e328356e91c -
Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan Adults
This study investigates the impact of different meal conditions on the steady-state pharmacokinetics of lopinavir and ritonavir in HIV-infected Ugandan adults, revealing that a high-fat meal significantly reduces the bioavailability of both drugs compared to fasting.
DOI: 10.1097/QAI.0b013e3182567a35 -
Protease Inhibitor-Induced Carbamazepine Toxicity
This study presents a case of carbamazepine toxicity in a patient with HIV, attributed to the interaction with the protease inhibitor ritonavir, highlighting the need for careful monitoring of antiepileptic drug levels in patients receiving antiretroviral therapy.
DOI: 10.1097/00002826-200007000-00009 -
The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects
This study investigates the pharmacokinetic interaction between ritonavir and saquinavir, demonstrating that ritonavir enhances saquinavir plasma concentrations independently of its dosage, based on data from 97 healthy subjects.
DOI: 10.1046/j.1468-1293.2002.00090.x -
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters
This study evaluates the inhibitory effects of ketoconazole and alternative CYP3A4/5 inhibitors (ritonavir, clarithromycin, and itraconazole) on 13 clinically relevant drug transporters, revealing unique inhibition profiles and implications for drug-drug interactions.
DOI: 10.1124/dmd.115.067744 -
Effect of Efavirenz, Nevirapine, Etravirine, and Raltegravir Administration on the Pharmacokinetics of Ritonavir-Boosted Darunavir in a Population of HIV-Infected Patients
A population pharmacokinetic analysis of HIV-infected patients on ritonavir-boosted darunavir evaluated how coadministration of efavirenz, nevirapine, etravirine, and raltegravir affects darunavir exposure; nevirapine and efavirenz increased clearance and lowered trough concentr…
DOI: 10.1089/aid.2012.0188